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Background: Previous research has suggested that pelvic floor muscle training (PFMT) offers
a therapeutic benefit in patients with overactive bladder.
Methods:Weconducteda single-blind, randomized trial of pelvic floormuscle training (PFMT)
as comparedwith usual care. The intervention group (n¼ 54) received a 6-month a nurse-led
long-term pelvic floor muscle training program (three sessions a day, 15e20 times per ses-
sion) and the control group (n ¼ 53) received usual care. All patients received 3-month sol-
ifenacin succinate tablets (5 mg e once daily). The treatment outcomes were measured by
theModified Oxford Scale (MOS), Overactive Bladder Symptom Score (OABSS) and the King's
Health Questionnaire (KHQ) at baseline, 3 months and 6 months respectively.
Results: Of the 91 randomly assigned patients, 46 patients in the PFMT group and 45 pa-
tients in the control group completed the trial. The trial revealed statistically significant
differences between groups in pelvic muscle strength at 3 months following the inter-
vention (p < 0.05), but no significant difference was found between two groups in OABSS
scores (p > 0.05). In regards to quality of life, the experimental group showed significant
improvements compared to the control group on 6 of 10 domains (p < 0.05). At 6 months,
there were significant improvements in OABSS scores and quality of life in the experi-
mental group compared to the control group (p < 0.05). No adverse events were observed.
Conclusion: A nurse-led long-term (6 months) pelvic floor muscle training programmay alle-
viate OAB symptoms effectively and improve the quality of life more than a short term (3
months) pelvic floor muscle training program combined with solifenacin succinate tablets.
Copyright © 2015, Chinese Nursing Association. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).un).
Nursing Association.
Association. Production and hosting by Elsevier (Singapore) Pte Ltd. This is an open access
://creativecommons.org/licenses/by-nc-nd/4.0/).
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ized primarily by urgency, with or without urgency urinary
incontinence, usually with frequency and nocturia [1]. Based
on this definition, the first large population-based survey to
evaluate the prevalence of all LUTS in five countries in 2006
reported the global prevalence of OAB was 11.8% (10.8% men;
12.8% women) [2]. In 2010 Yuliang Wang et al. reported the
prevalence of OAB was 6.0% in china [3], though it is lower
than most of other countries, it still brings detrimental im-
pacts on patients' health-related quality of life [3,4] such as
emotional distress, sexual problems, and influence on re-
lationships with family members [2,5], and in recent years,
OAB has become a hot issue among urologists.
Because of symptom variability, for a long time, OAB is
believed to be a chronic condition that has no cure. In recent
years, A focus was gradually placed on behavioral therapy [6].
Behavioral therapy includes bladder training, pelvic floor
muscle training (PFMT), biofeedback, dietary changes, and
multi-component approaches that combine bladder training
with PFMT and/or biofeedback. And behavioral therapy and
pharmacologic treatment were recommended to be the first
line treatment according to the 2011 Chinese Urological As-
sociation (CUA) guideline [7]. Although behavioral therapy for
OAB has been used to manage urinary incontinence for more
than 50 years [8], the outcomes are still controversial. Some
studies reported behavioral approaches can be effective in
reducing episodes of incontinence and daily voids [9,10], some
studies reported managing OAB with behavioral approaches
treatment is moderate to weak for short term outcomes and
weak for long term outcomes and harms [1,11]. As part of
behavioral treatment, pelvic floor muscle training (PFMT),
defined as repetitive selective voluntary contraction and
relaxation of specific pelvic floor muscles [12], can modulate
overactive bladder syndrome through both afferent and
efferent stimuli of the detrusor muscle. Afferent stimuli from
pelvic organs such as the vagina, cervix, and rectum can
inhibit the sacral preganglionic innervation to the bladder as
well as increase urethral pressure through the viscer-
alevisceral reflex otherwise called the guarding reflex [12]. It
was originally suggested for patients with stress incontinence
since it is useful in inhibiting detrusor contractions. Because a
detrusor involuntary contraction (detrusor overactivity) was
observed in urodynamic study. It is spontaneous or provoked,
during the filling phase, involving a detrusor pressure rise of
greater than 15 cm H2O above baseline [13]. Based on the
above mentioned outcome, we speculate PFMT can be used to
control bladder function in OAB patients. PFMT was also in-
tegrated into the treatment of urge incontinence and OAB as
part of a broader behavioral urge suppression strategy in
recent years [8]. However, a lack of consistency in study
design, and comparison groupsmakes it impossible to provide
consistent results regarding the effectiveness of PFMT in pa-
tients with OAB across studies. Wang et al. found that
biofeedback associated pelvic floor muscle exercises resulted
in greater change in muscle strength than electrical stimula-
tion, but the clinical significance of the change was not
examined [14]. Song C reported no additional benefit forreducing incontinence episodes or voids per day was found by
adding behavioral treatments to pharmacologic approaches
for reduction in incontinence [15e17]. Wyman JF finded sig-
nificant improvement in quality of life immediately after
intervention, but not at three months [18]. Based on the above
mentioned information, the purpose of the current study was
to investigate whether a 6-month PFMT combined with 3-
month- tolterodine can improve OAB symptoms and quality
of life in female patients with primary OAB (See Fig. 1).2. Methods
2.1. Study participants
We conducted the trial from January 2012 through February
2013 at urological clinic of hospital, a comprehensive Hospital
in Hangzhou, Zhejiang Province. The institutional review
board of the hospital approved the study protocol. All eligible
participants were diagnosed by one doctor who is the expert
in overactive bladder at the urology clinic as primary over-
active bladder using the 2002 ICS definition [1]. The inclusion
criteria were as following: age 18 years, women who have a
history of sexual life; Symptoms of OAB 3 months; Over-
active Bladder Symptom Score (OABSS) 5; Urinary frequency
8 times/per day; At least 1 urgency in three days before being
recruited;With orwithout urgency urinary incontinence; all of
women will receive the treatment with tolterodine, no other
antimuscarinic drugs. The exclusion criteria included preg-
nancy or planned pregnancy within one year, deafness,
neurologic disorders, diabetes mellitus, and urinary tract
infection. All patients provided written informed consent (See
Fig. 2).
2.2. Study design
We assigned participants to PFMT or the control intervention
in three randomization cycles, using computer-generated
numbers. The randomized treatment assignments were
sealed in opaque envelopes and were opened individually for
each patient who agreed to be in the study.
Patients were randomly assigned, using computer-
generated random assignment in a 1:1 ratio, to intervention
group and control group. As randomization will be conducted
via a centralized com puter randomization ser vice, allocation
will be concealed until the point of randomization.
2.3. Intervention
At first, participants in experiment group were asked to
perform PFMT under the guidance of a researcher, in which
initially the researcher introduced the PFMT, explained its
anatomy and principle. Then, participants were placed in li-
thotomy position, the researcher put her forefinger and mid-
dle finger into the participants' vagina after paraffin oil
lubrication, the participants were asked to contract the pelvic
floor muscles for 5e10 seconds, relax for 10 seconds after. If
they could feel pressure surrounding the fingers, it was
considered as correct muscle contraction. If participants
Assessed for eligibility
(n=123)
Excluded (n=16)
Not meeting inclusion criteria (n=9)
Declined to participate (n=7)
Randomized (n=107)
Allocated to intervention (n=54)
Received allocated intervention (n=54)
Did not receive allocated intervention (n=0)
Allocated to intervention (n=53)
Received allocated intervention (n=53)
Did not receive allocated intervention (n=0)
Lost to follow-up (give reasons) (n=2)
Discontinued intervention (give reasons) (n=6)
1 of them combined with infection, 2 of them 
combined TCM. 3 of them could not tolerate the 
side effect of the medicine
Lost to follow-up (give reasons) (n=3)
Discontinued intervention (give reasons) (n=5)
1 of them combined with infection, 2 of them 
combined TCM. 2 of them could not tolerate the 
side effect of the medicine
Analysed (n=46)
Excluded from analysis (n=0)
Analysed (n=45)
Excluded from analysis (n=0)
Fig. 1 e Flow diagram of the progress through the phases of a parallel randomized trial of two groups (that is, enrollment,
intervention allocation, follow-up, and data analysis).
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pressure until correct contraction was achieved. When par-
ticipantswent back home and pelvic floormuscle trainingwas
conducted three sessions per day, 15e20 times per session,
along with a health education program. When participants
return to the clinic at month 1 and month 3, researcher
measured the pelvic floor muscle strength, then conduct herFig. 2 e Changes in the OABSS scorrect contraction until all participant could do correct
muscle contraction. Apart from this, a face to face education
program on OAB was provided by the researcher which
included professional information related to OAB, such as
lifestyle and drinking habit change at first intervention and
booklet were provided to participants. For instance, we asked
participants to limit fluid intake and cut back on caffeine, teacores over the study period.
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include urge suppression or urge control techniques were
provided in booklet. We also gave them the researcher's cell
phone number to keep close contact with the participants,
and also we called participants twice a week tomake sure that
the participants followed the Protocol. Participants in the
control group received the health education program only. All
participants in two group received the treatment with tolter-
odine sustained-release tablets (5 mg qd) for 3 months.
Adverse effects and adherence with all the treatments were
registered in a training diary updated by the research nurse
during each clinic visit.
2.4. Outcome measures and follow-up
The primary outcomemeasure was the Modified Oxford Scale
(MOS) [19]. which is themost commonly used scale for grading
pelvic floor muscle function. This is a 6-point scale described
as: 0 ¼ no contraction; 1 ¼ flicker; 2 ¼ weak; 3 ¼ moderate
(with lift); 4 ¼ good (with lift); 5 ¼ strong (with lift). It is a low
cost technique, and is relatively easy to conduct once suffi-
cient instruction has been given and is well tolerated by pa-
tients. We measured the MOS for all participants at baseline
and 3 months during trial respectively. These measurements
were all obtained by the same clinical research nurse (See
Fig. 3).
Secondary outcomes during the 12-week intervention
included Overactive Bladder Symptom Score (OABSS) [20] and
the King's Health Questionnaire (KHQ) [21]. OABSS are tradi-
tionally used to qualify OAB symptom and measure the
intervention effects [20]. It contains four questions: the day-
time frequency of urination (2 points), nocturia (3 points),
urgency (5 points), and urgent incontinence (5 points). The
total score are the sum scores of the four questions. The
participants were recruited if they had a score of no less than
5. OABSS was measured for all participants at baseline, 3
months and, 6 months during trial respectively.
To assess health related quality of life, all participants were
asked to complete the King's Health Questionnaire (KHQ) [21]
at baseline and 3, 6 months respectively. KHQ is a measure of
health related quality of life consists of multi item domains
(role limitations, physical limitations, social limitations, per-
sonal relationships, emotions, sleep and energy, and severity
(coping) measures), two one-item questions (incontinence
impact and general health perceptions) and a multi itemFig. 3 e Changes in the MOS scsymptom severity domain. The 7 multi-item domains and the
2 single-item domains of the KHQwere scored from 0 (best) to
100 (worst). The Symptom Severity domain was scored from
0 (best) to 30 (worst) [22].
Throughout the entire intervention period, we monitored
adverse events, using a standard adverse event case report
form at each visit. This form included a description of all
unanticipated benefits and undesirable experiences, particu-
larly falls and exacerbations of fibromyalgia symptoms. Lack
of an effect with PMFT or wellness education was not
considered an adverse event (See Fig. 4).
2.5. Statistical analysis
We analyzed only the data for those patients who completed
the whole trial. For statistical analysis, SPSS17.0 software was
used. Chi-square test was used to compare the demographic
characteristics between groups. ANOVA of repeated mea-
surement was used to compare the effects of pelvic floor
muscle training on primary overactive bladder in female pa-
tients. A P value of less than 0.05 was considered statistically
significant.3. Result
3.1. Baseline characteristics of the participants
Between January 2012 through February 2013, we screened 107
patients .54 in experiment group, 53 in control group. Sixteen
(15.0%) participants dropped out. Among them, five in exper-
iment group and three in control group could not tolerate the
side effects of tolterodine, such as dry mouth and impaired
urination, etc. Four participants in the experiment group
dropped out because they found the PFMT intervention un-
pleasant in some way. Another two from the control group
quit the trial and changed to take traditional Chinese medi-
cine instead. All of them dropped out at 2 weeks. 91 eligible
participants were randomly assigned in equal numbers to
either the PFMT intervention or the control intervention
(Table 1). 46 from the experimental group and 45 from the
control group. There were no significant demographic differ-
ences between the final subsets of those groups who actually
completed the study. The baseline demographics of the two
groups were outlined in Table 1.ores over the study period.
Fig. 4 e Changes in the KHQ domain scores over the study period: Changes in themedian KHQ Domain scores over the study
period: (i) General Health Perception' (GHP); (ii) Incontinence Impact (II); (iii) Role limitations (RL); (iv) Physical Limitation (PL);
(v) Social Limitations (SL); (vi) Personal Relationships (PR); (vii) Emotions (E); (viii) Sleep/Energy (S/E); (ix) Severity Measures
(SM); (x) Symptom Severity score (SSS).
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The effects on OAB symptom and change of pelvic floor
muscle strength were shown in Table 2. From this table, we
can see there is no difference between two groups at baseline.
It has statistical differences between pre-intervention and
post-intervention (F ¼ 5.942, p ¼ 0.008). F value in experiment
group and control group are (245.325, 147.094), p< 0.001.
OABSS scores in both group reached the highest level at
baseline, then gradually go down and reached the lowest
score. We also found there was no statistical differences
(t ¼ 0.729, p¼ 0.468) between two groups at 3 months, but it
has statistical differences at 6 months between groups
(t ¼ 3.099, p ¼ 0.003).
Regards to MOS, there is no difference between two groups
at baseline. It has statistical differences between pre-
intervention and post-intervention (F ¼ 14.574, p < 0.001). F
value in experiment group and control group are (72.911,
17.875), P< 0.001. MOS scores in both group improved at 3
months. Total effect also shown statistical differences be-
tween groups at 3 months (F ¼ 14.574, P < 0.001).
A reduction in scores of the KHQ in both groups indicates
better health related quality of life. As Table 3 shown there is
no difference between two groups at baseline. After inter-
vention, six of 10 domains include “Incontinence impact,
Role limitations, Physical limitations, Social limitations,
Emotions, Symptom severity” has statistical differences be-
tween groups at 3 months (p< 0.05). All domains except
“General health perception” has statistical differences
(p< 0.05) at 6 months. Scores of domains in both groups at
baseline got the highest level, then gradually go down at 3
months and reached the lowest scores at 6 months.
Compared to each time point, all domains has statistical
differences (p < 0.001) in group.Table 1 e Demographic characteristics of 91 participants (n ¼ 9
EG (n¼ 46
n (%)
Marital status Married 40 (87.0)
Unmarried 6 (13.0)
Income (RMB/month) >5000 1 (2.2)
3000e5000 44 (95.7)
<3000 1 (2.2)
Education level Senior high school or above 13 (28.3)
Junior high school 27 (58.7)
Primary school or under 6 (13.0)
Mode of delivery Vaginal 30 (76.9)
Cesarean 9 (23.1)
Both vaginal and cesarean 0 (0)
Delivery history None 7 (15.2)
1 25 (54.3)
2 11 (23.9)
3 3 (6.5)
Duration of OAB (years) >20 4 (8.7)
10e20 7 (15.2)
5  years < 10 29 (63.0)
<5 6 (13.0)
aMeans Fisher exact probability test.4. Discussions
In current study,we find pelvic floormuscle training improved
the pelvic floor muscle strength of the experiment group
significantly at 3 months and 6 months compared to the
control group as Table 2 showed. The result is similar to report
by Aslan et al. that a significant increase in pelvic floormuscle
strength in patients with urgency urinary incontinence after 8
weeks and 6 months [23]. Wang AC et al. also reported that a
pelvic floor muscle exercise can significantly increased pelvic
floor muscle strength parameters compared to vaginal elec-
trical stimulation after 12 weeks [14]. However, our results
showed no evidence supported pelvic floor muscle training
enhance the effectiveness of tolterodine for reducing episodes
of incontinence and voiding at 3 months. As Table 2 showed
that OABSS score decreased in experiment group at 3 months
compare to baseline in group, this outcome supported that
tolterodine (extended release) might be offered as a treatment
for overactive bladder syndrome, as it is associated with sig-
nificant objective clinical improvement. But there were no
statistically significance between two groups until 6 months.
Therefore, it is important to note that stronger pelvic floor
muscle does not mean lower score on OABSS. The result is
similar towhat is reported by Alex C et al. [14]. OABSS scores in
experiment group were significantly lower than the control
group at 6 months. It means that long term PFMT combined
with pharmacotherapy may relieve overactive bladder syn-
drome effectively. The outcome is similar to the study re-
ported by Ng SC who indicated that a home-based pelvic floor
muscle exercise could improve symptoms significantly in the
study group at 6 months [24]. Therefore, we conclude that a 6
months pelvic floor muscle training may be better to relieve
the OAB symptoms. So behavioral interventions combined1).
) CG (n ¼ 45) Comparisons between two groups
n (%) x2 p
41 (91.1) 0.401 0.526
4 (8.9)
1 (2.2) 0.001 0.999
43 (95.6)
1 (2.2)
9 (20.0) 0.874 0.646
30 (66.7)
6 (13.3)
32 (80.0) 2.652 0.265
6 (15.0)
2 (5.0)
5 (11.1) 0.599 0.897
27 (60.0)
11 (24.4)
2 (4.4)
1 (2.2) 3.761 0.288
4 (8.9)
36 (80.0)
4 (8.9)
Table 2 e The OABSS, MOS scores of the participants at baseline and 3, 6 months ðX±SDÞ.
Baseline 3 months 6 months Total F P
OABSS
EG (n ¼ 46) 7.61 ± 2.28 2.67 ± 2.80 1.13 ± 1.93 3.80 ± 3.63 245.325 <0.001
CG (n ¼ 45) 7.44 ± 2.41 3.07 ± 2.31 2.47 ± 2.18 4.33 ± 3.19 147.094 <0.001
Total 7.53 ± 2.33 2.87 ± 2.56 1.79 ± 2.15 4.06 ± 3.42 383.123b <0.001b
t 0.335 0.729 3.099 1.560a F ¼ 5.942c
P 0.739 0.468 0.003 0.215a p¼ 0.008
MOS
EG (n ¼ 46) 2.87 ± 0.65 3.57 ± 0.58 3.22 ± 0.71 72.911 <0.001
CG (n ¼ 45) 2.80 ± 0.55 3.09 ± 0.67 2.94 ± 0.63 17.875 <0.001
Total 2.84 ± 0.60 3.33 ± 0.67 3.08 ± 0.68 85.383b <0.001b
t 0.550 3.625 5.399a F ¼ 14.574c
p 0.584 <0.001 0.022a p< 0.001c
a F statistic and p value of group effect.
b F statistic and p value of time effect.
c F statistic and p value of cross over effect.
Table 3 e KHQ domains scores of the 91 participants at baseline and at 3, 6 months ðX±SDÞ.
KHQ domain Time EG (n ¼ 46) CG (n ¼ 45) F p
General health perception Baseline 65.22 ± 15.35 61.11 ± 12.56 4.281b 0.019b
3 month 42.39 ± 18.16 45.56 ± 16.24
6 month 33.70 ± 17.65 40.56 ± 16.24
Total 47.10 ± 21.59b 49.07 ± 17.39b
Incontinence impact Baseline 86.23 ± 23.91 76.30 ± 29.83 11.114b 0.001b
3 month 36.23 ± 34.31 51.19 ± 34.43
6 month 18.84 ± 27.81 37.78 ± 34.53
Total 47.10 ± 40.63a 55.09 ± 36.47a
Role limitations Baseline 27.53 ± 25.14 34.44 ± 30.86 2.705b 0.087b
3 month 5.07 ± 13.08 21.19 ± 27.93
6 month 3.63 ± 9.89 13.04 ± 22.00
Total 12.08 ± 20.41a 22.89 ± 28.40a
Physical limitations Baseline 46.73 ± 21.27 38.14 ± 28.12 11.231b 0.001b
3 month 10.86 ± 16.92 21.84 ± 22.97
6 month 4.71 ± 12.49 11.84 ± 16.89
Total 20.77 ± 25.29a 23.94 ± 25.39a
Social limitations Baseline 31.38 ± 24.26 24.43 ± 24.10 8.875b 0.001b
3 month 7.97 ± 17.15 16.78 ± 20.59
6 month 3.14 ± 9.83 8.63 ± 15.86
Total 14.16 ± 21.79a 16.61 ± 21.32a
Personal relationships Baseline 24.72 ± 27.30 18.00 ± 24.81 5.217b 0.016b
3 month 9.75 ± 14.63 10.96 ± 18.04
6 month 1.90 ± 5.23 7.63 ± 14.78
Total 12.12 ± 20.36a 12.2 ± 19.99a
Emotions Baseline 51.90 ± 27.81 44.06 ± 30.06 8.374b 0.002b
3 month 12.79 ± 16.38 22.70 ± 26.99
6 month 5.31 ± 13.39 14.80 ± 20.50
Total 23.33 ± 28.66a 27.19 ± 28.77a
Sleep/energy Baseline 34.42 ± 22.06 32.23 ± 26.45 2.420b 0.106b
3 month 11.23 ± 17.93 16.66 ± 21.02
6 month 4.35 ± 11.88 10.74 ± 16.72
Total 16.67 ± 21.87a 19.88 ± 23.44a
Severity measures Baseline 15.77 ± 18.02 13.16 ± 16.99 5.690b 0.010b
3 month 4.53 ± 9.42 9.08 ±12.92
6 month 2.18 ± 5.95 6.30 ± 10.83
Total 7.49 ± 13.52a 9.51 ± 14.00a
Symptom severity Baseline 8.59 ± 2.48 8.33 ± 2.88 7.0033b 0.002b
3 month 3.17 ± 3.23 4.73 ±3.60
6 month 1.61 ± 2.68 3.20 ± 3.42
Total 4.46 ± 4.10a 5.42 ± 3.94a
a p < 0.05 of group effect.
b F statistic and P value of crossover effect.
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improvements comparable to medications alone. Even it is
reported that the combination group had greater perceived
improvement at 10 weeks, but no differences by group at 8
months [25]. For us, we believe that we should pay more
attention on how combinations of behavioral intervention
and pharmacologic treatment, it may take more influence on
the effects of treatment. And also how long pelvic floormuscle
training should be sustained and the adherence to interven-
tion should be taken into consideration. Compliance with
PFMT is a problem with discouraging long-term adherence to
PFMT programs, it is reported adherence rates as low as 50%
[26,27]. Some strategies were taken into current trial to
improve patient compliance. First, we offered an education
booklet and the researcher's cell phone number to keep close
contact with the participants. Secondly, we call participants
twice a week to make sure that the participants follow the
protocol. At last, participants in both groups received health
education, which can stimulate patients to follow the in-
struction to change their bad lifestyle, and encourage them to
adhere to PFMT. In addition, there is low cost associated with
PFMT, participants can easily grasped after researcher con-
ducted, which is welcomed by our participants. In our study,
the compliance rate with PFMT hit 90%.
Secondly, PFMT have a beneficial effect on health related
quality of life. This was reﬂected by the decreased scores in
experiment group on 5 of the 10 domains at 3 months
including “Incontinence impact”, “Role limitations”, Physical
limitations”, “Social limitations”, “Symptom severity”. Vaart
et al. [28] reported that women with OAB symptoms were
especially limited in their mobility and that urge incontinence
was associated with feelings of embarrassment. Compared to
the findings of Vaart et al., [28] the responses to limitation of
mobility (domain include physical limitation, Social limita-
tions, Symptom severity) revealed the statistically significant
post-intervention differences between the groups.” as the
result,participants reported Incontinence impact ”also
improved. At 3 months, domains of “General health percep-
tion” and “Personal relationship” had no difference between
two groups. The outcomewas similar to the study reported by
Kubota Y who treated OAB with an antimuscarinic drug for 12
weeks [29]. Furthermore, domains of Emotions, Sleep/Energy
were also no significantly different at 3 months, which is
different from Alex C's study [18]. It may be related to a more
conservative way of expression of Chinese people [30].
Different cultural background may have some influence here.
At 6 months, all domains except “General health perception”
have statistical differences between two groups at 6 months.
Regards to the “General health perception”, although scores of
this domain decreased significantly from baseline to six
months intervention in both groups, still has no statistical
differences between two groups at 6 months. but the total
effect shown it is improved during the intervention. We noted
that the history of OAB of the participants 5 years hit 87%e
91.1%, some of them suffering for more than 20 years. It is
hard to reach a obviously satisfied with six months interven-
tion. To conclude above mentioned that pelvic floor muscle
training combined with pharmacotherapy may result in a
better quality of life in female patients with primary over-
active bladder.Our study was limited by the fact that we only include fe-
male participants, therefore may not reflect generalized
practice patterns. Furthermore, our sample size limited the
comprehensive conclusions that can be drawn. Further
studies are needed to choose the optimal training tool for
PFMT. And also a longer follow up more than 6 months is
highly recommended. However, our trial demonstrated that
pelvic floor muscle training could relieve OAB symptom and
have a beneficial effect on health related quality of life mea-
surements. In our study, significantly greater post-
intervention changes in pelvic floor muscle strength, OABSS
scores, and scores of KHQ were noted after both PFMT group
and control group. Moreover, we noted having greater muscle
strength is not the same as having good management of OAB.
Longer PFMT have bettermanagement of OAB in symptoms or
greater improvement in quality of life.5. Conclusions
As the first line treatment, the behavioral intervention is
indeed take effect. Pelvic floor muscle training can improve
pelvic floor muscle strength significantly, relieve symptoms
and improve the quality of life. (3 months) may not be
adequate for a complete symptom relief and improvement of
quality of life. (6 months) pelvic floor muscle training is
promising to alleviate OAB symptoms effectively and
improve the overall quality of life of the patients. Long term
(more than 6 months) PFMT should be introduced into
treatment and the how long PFMT is the best for patients to
manage the OAB should be recommend to research in the
coming days.6. Limitations
Our study was limited by the fact that we only include female
participants, therefore may not reflect generalized practice
patterns. Furthermore, our sample size limited the compre-
hensive conclusions that can be drawn. Further studies are
needed to choose the optimal training tool for PFMT. And also
a longer follow up more than 6 months is highly recom-
mended. However, our trial demonstrated that pelvic floor
muscle training could relieve OAB symptom and have a
beneficial effect on health related quality of life measure-
ments. In our study, significantly greater post-intervention
changes in pelvic floor muscle strength, OABSS scores, and
scores of KHQ were noted after both PFMT group and control
group. Moreover, we noted having greater muscle strength is
not the same as having good management of OAB. Longer
PFMThave bettermanagement of OAB in symptoms or greater
improvement in quality of life.r e f e r e n c e s
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